RH5.1/Matrix-M: A Promising Blood-Stage Malaria Vaccine

The RH5.1/Matrix-M malaria vaccine shows promise as a component of future malaria prevention strategies, according to a GlobalData report.

A study conducted in Burkina Faso and the UK found the vaccine to be safe, 55% effective against clinical malaria, and over 80% effective against severe cases. The findings, published in The Lancet Infectious Diseases, highlight its potential to complement existing vaccines like GSK’s Mosquirix and Serum Institute’s R21/Matrix-M.

Currently, 11 other malaria vaccines are in Phase II trials, but none are in advanced stages of development. Despite progress, malaria remains a significant burden, particularly in Africa.